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Objectives: Weekly monitoring of European all-cause excess mortality, the EuroMOMO network,
observed high excess mortality during the inﬂuenza B/Yamagata dominated 2017/18 winter season,
especially among elderly. We describe all-cause excess and inﬂuenza-attributable mortality during the
season 2017/18 in Europe.
Methods: Based on weekly reporting of mortality from 24 European countries or sub-national regions,
representing 60% of the European population excluding the Russian and Turkish parts of Europe, we
estimated age stratiﬁed all-cause excess morality using the EuroMOMO model. In addition, age stratiﬁed
all-cause inﬂuenza-attributable mortality was estimated using the FluMOMO algorithm, incorporating
inﬂuenza activity based on clinical and virological surveillance data, and adjusting for extreme
temperatures.
Results: Excess mortality was mainly attributable to inﬂuenza activity from December 2017 to April 2018,
but also due to exceptionally low temperatures in February-March 2018. The pattern and extent of
mortality excess was similar to the previous A(H3N2) dominated seasons, 2014/15 and 2016/17. The
2017/18 overall all-cause inﬂuenza-attributable mortality was estimated to be 25.4 (95%CI 25.0-25.8) per
100,000 population; 118.2 (116.4-119.9) for persons aged 65. Extending to the European population this
translates into over-all 152,000 deaths.
Conclusions: The high mortality among elderly was unexpected in an inﬂuenza B dominated season,
which commonly are considered to cause mild illness, mainly among children. Even though A(H3N2) also
circulated in the 2017/18 season and may have contributed to the excess mortality among the elderly, the
common perception of inﬂuenza B only having a modest impact on excess mortality in the older pop-
ulation may need to be reconsidered. J. Nielsen, Clin Microbiol Infect 2019;25:1266
© 2019 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Mortality in temperate countries, in particular among senior
citizens, exhibits a marked seasonality, with higher mortality in the
winter period. Excess mortality may vary considerably between
countries and from season to season [1e7]. One of the main drivers
of increased winter mortality is seasonal inﬂuenza, however sea-
sonal transmission of other communicable diseases, such as RSV
and enteric infections, as well as the effect of extreme ambient
temperatures may also contribute [8,9].
Since 2009, the European network for monitoring of excess
mortality for public health action, EuroMOMO (www.euromomo.
eu), has monitored weekly all-cause, age-speciﬁc mortality in
real-time in participating European countries and provided pooled
estimates of excess mortality (observed minus expected), using the
EuroMOMOmodel [10]. These estimates are published on a weekly
basis and included in the weekly FluNewsEurope bulletin (www.
FluNewsEurope.org) to assess the inﬂuenza situation in Europe.
Recently, the EuroMOMO model was supplemented with another
time-series regression model, FluMOMO, which includes indicators
of inﬂuenza activity and extreme temperatures [7]. The aim of this
model is to obtain timely estimates of inﬂuenza-attributable mor-
tality adjusted for extreme temperatures.
From December 2017 a marked increase in all-cause excess
mortality was observed within the participating countries, espe-
cially inwestern and southern European countries, and particularly
among elderly (65 years or older). At the same time, most countries
reported rates of Inﬂuenza Like Illness (ILI) reaching moderate
levels, while only a few countries reported higher levels compared
with recent seasons. However, in some countries number of inﬂu-
enza hospitalisations and intensive care admissions reached or
exceeded peak levels of recent inﬂuenza seasons [11]. Overall, the
dominant inﬂuenza type was B/Yamagata followed by inﬂuenza A,
with both A(H1N1)pdm09 and A(H3N2) circulating in varying
patterns between countries [12]. The WHO recommended vaccine
components for the trivalent vaccine in the 2017/18 season on the
Northern Hemisphere contained B/Victoria [13].
Knowledge about the burden of seasonal inﬂuenza is crucial to
informing policies for prevention and control of inﬂuenza, in
particular seasonal inﬂuenza vaccination programs. Hence, being
able to quantify the mortality-burden of inﬂuenza, and associate it
to circulating seasonal inﬂuenza viruses, adds valuable information.
The aim of the present study is to describe excess all-cause
mortality and estimate all-cause mortality attributable to inﬂu-
enza during the season 2017/18 in Europe, using the EuroMOMO
and FluMOMO models and available inﬂuenza surveillance and
temperature data.
Methods
All-cause excess mortality, the EuroMOMO model
Countries participating in the EuroMOMO network collect data
on number of all-cause deaths weekly, and undertake national
analyses using the EuroMOMO model [4].
The EuroMOMO hub at Statens Serum Institut in Denmark
receive mortality data aggregated by week and age group from the
participating countries, and conducts country-stratiﬁed pooled
analyses of these data [10]. We estimated the pooled excess mor-
tality for the winter season 2017/18 using all-cause mortality data
fromweek 1/2014 to week 20/2018, from 24 participating national
or sub-nation states (Austria, Belgium, Berlin (Germany), Denmark,
England (UK), Estonia, Finland, France, Greece, Hesse (Germany),
Hungary, Ireland, Italy, Luxembourg, Malta, Netherlands, Northern
Ireland (UK), Norway, Portugal, Scotland (UK), Spain, Sweden,
Switzerland, Wales (UK)), further on referred to as countries.
Mortality data reported to the EuroMOMO hub in week 27/2018
were used.
Inﬂuenza-attributable mortality, the FluMOMO model
The FluMOMO model is a multiplicative Poisson regression
time-series model with overdispersion, ISO-week as time unit and
a post-estimation correction for skewness of the residuals by
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applying a 2/3-power correction, and have been described in detail
elsewhere [7].
To estimate inﬂuenza-attributable mortality for each country
we used the all-cause mortality data from EuroMOMO, aggregated
by week and age group, combined with weekly inﬂuenza activity
(IA) and temperature data. As IA indicator, we used the Goldstein
index [14], deﬁned as the ILI rate multiplied by the Positive Per-
centage (PP), i.e. proportion of sentinel inﬂuenza-positive speci-
mens among all sentinel specimens tested for inﬂuenza. This
indicator combines the clinical measure of inﬂuenza circulating in
the population (ILI) with PP to take into account that not all ILI cases
are due to inﬂuenza. In countries or seasons, where ILI data were
unavailable, Acute Respiratory Infection (ARI) rates or alternatively
the indicator Intensity (Low, Medium, High or Very High; a quali-
tative measure, recommended to be based on the Moving Epidemic
Method [15]) was used. ILI/ARI/Intensity data as well as virology
data were downloaded from the TESSy database at the European
Centre for Disease Prevention and Control (ECDC) [16,17]. Virolog-
ical data registered in TESSy are not age differentiated, therefore the
same all-ages virological data had to be used in each age group.
Ambient daily temperature data from weather stations in each of
the participating countries was captured from the National Oceanic
and Atmospheric Administration (NOAA) [18]. Weekly extreme
temperatures were deﬁned as degrees of temperature above the
expected weekly average maximum temperatures or below the
weekly average minimum temperature [7].
We estimated the pooled mortality attributable to inﬂuenza and
extreme temperatures for the winter seasons 2012/13 to 2017/18
using country-stratiﬁed pooled analyses, thus adjusting for
differences in baselines between countries. The analyses were
conducted for each season using data from the ﬁve preceding
seasons.
Clinical and virological inﬂuenza datawere downloaded inweek
27/2018, as was ambient temperatures.
Mortality rates, background populations
Based on the estimated number of deaths, mortality rates were
calculated using national or sub-national population data as of
January 1st every year, downloaded from EuroSTAT (https://ec.
europa.eu/eurostat/) in week 27/2018, and linearly interpolated
through the year.
Results
Overall, the European 2017/18 inﬂuenza season was dominated
by inﬂuenza B (Fig. 1). The weekly inﬂuenza PP was nearly two
times higher for inﬂuenza B than inﬂuenza A, however with some
variation between the participating countries.
All-cause mortality for all ages exceeded threshold levels (>þ2
z-scores) in all participating countries except in Greece. Excess
mortality was ﬁrst observed in Spain in week 46/2017 (Table 1),
followed by Scotland in week 47; England, Northern Ireland, and
Portugal in week 49; France, Ireland, and Italy in week 50; Norway,
Switzerland, and Wales in week 51; Denmark in week 52; Austria
and Netherlands in week 1/2018. Belgium and Hungary had two
weeks periods around New Year. Mortality in France, Norway, and
Switzerland returned to expected levels at the end of January and in
Fig. 1. Percentage inﬂuenza positive sentinel specimens, pooled from 24 European countries* by week of reporting and inﬂuenza virus type, week 40/2017 to week 20/2018.
* Participating countries: Austria, Belgium, Berlin (Germany), Denmark, England (UK), Estonia, Finland, France, Greece, Hesse (Germany), Hungary, Ireland, Italy, Luxembourg, Malta,
Netherlands, Northern Ireland (UK), Norway, Portugal, Scotland (UK), Spain, Sweden, Switzerland, Wales (UK)
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Scotland in February. For the other countries, the excess continued,
and from February-March 2018 Belgium, Estonia, Finland, France,
Hesse, Berlin, Luxembourg, Norway, Malta, and Sweden had mor-
tality exceeding expected levels. Countries in the southwestern part
of Europe and Scotland experienced particularly high all-cause
excess mortality during the 2017/18 inﬂuenza season (high z-
score value in Table 1).
The pooled estimates of excess all-cause mortality of the 24
participating countries rose sharply for the age groups 15-64 years
and 65 years or older in week 48/2017, exceeding 4 z-scores above
baseline in week 49/2017 (Fig. 2). Over the season, there were two
waves of excess mortality, the ﬁrst peak in the beginning of 2018
and a second less pronounced peak in February-March 2018.
Previously published pooled estimates of excess mortality ac-
cording to the EuroMOMO algorithm for the 2012/13 to 2016/17
seasons [19] and the estimates for the 2017/18 season are shown in
Table 2. The excess all-cause mortality rate, i.e. the deviation from
the estimated baseline, for the 2017/18 season was 33.8 (95%CI
32.8-34.9) per 100,000 population across all ages, which approxi-
mated the high mortality rates observed in the two A(H3N2)
dominated seasons 2014/15 and 2016/17 (Fig. 3). Mortality rates
were highest among those aged 65 years and older, whereas the
mortality rate among children <15 years was lower than the pre-
vious seasons.
According to the FluMOMOmodel, excess mortality in the 2017/
18 season could largely be attributed to seasonal variation in
inﬂuenza activity (Fig. 4). Furthermore, the FluMOMO model indi-
cated that the second late peak inmortality to some extent could be
attributed to the exceptionally cold temperatures in February-
March 2018 in addition to a declining, but still prominent excess
mortality attributable to inﬂuenza.
The pooled 2017/18 mortality attributable to inﬂuenza was
estimated to be 25.4 (25.0-25.8) per 100,000 population for all ages,
slightly below the 2014/15 and 2016/17 seasons (Table 2) but
following the pattern of these seasons (Fig. 5). In the age group 15
to 64 years, the inﬂuenza-attributable mortality was estimated to
be 3.1 (3.1-3.2) per 100,000 population, which was signiﬁcantly
higher than the ﬁve previous seasons.
With the participation of 24 European countries corresponding
to a population of 361 million inhabitants (Tables 2 and 3), the
pooled analyses cover 60% (361/599) of the European population of
599 million, excluding the Russian and Turkish parts of Europe
(http://www.worldometers.info/world-population/europe-
population/). If we extend our results to this European population,
excess number of deaths in Europe during the 2017/18 season
would be 202 (196-209) thousand, and number of deaths attrib-
utable to inﬂuenza 152 (150-155) thousand.
Discussion
Seasonal inﬂuenza causes a major health burden [20], espe-
cially for the elderly and persons with underlying health condi-
tions. In addition to the direct effects of inﬂuenza infection,
underlying health conditions may be exacerbated leading to poor
health outcomes and even premature death. In this situation,
inﬂuenza or respiratory tract infection may not be registered as
cause of death. Hence, estimates of inﬂuenza-attributable mor-
tality based on all-cause rather than cause-speciﬁc mortality e.g.
respiratory deaths including inﬂuenza and pneumonia, is expected
to be higher. Inﬂuenza-attributable deaths coded as non-
respiratory deaths have been found to be at the same magnitude
as for respiratory inﬂuenza mortality [21,22]. Therefore, all-cause
mortality attributable to inﬂuenza may be expected to be around
the double of inﬂuenza mortality based on respiratory cause of
death alone.
Recently, a global study estimated average annual inﬂuenza-
associated respiratory mortality rates in Europe from 1999 to
2015 to be 3.1 to 8.0 per 100,000 population [23]. As expected,
these estimates are lower than the median of the all-cause esti-
mates of inﬂuenza-attributable mortality of 13.3 per 100,000
population (Table 3). However, considering, as mentioned, that
inﬂuenza-associated deaths from respiratory deaths may represent
Table 1
Weekly all-cause mortality for all ages exceeding the threshold level (þ2 z-scores) during the 2017/18 winter season by country, based on the EuroMOMO algorithm
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only half of all inﬂuenza-attributable deaths, corresponding to all-
cause mortality rates of roughly 6 to 16, the estimated rates from
the two studies are consistent.
The EuroMOMO pooled analyses showed that the 2017/18 sea-
sonal excess mortality started on the Iberian Peninsula and spread
across the southern and western parts of Europe, while mortality
tended to be within normal levels in the northern, eastern, and
central parts of Europe until February-March 2018, where Europe
experienced a period with exceptionally cold temperatures. The
FluMOMO pooled estimates of mortality attributable to inﬂuenza
activity adjusted for extreme temperatures showed a similar
pattern, including a marked elevated mortality attributable to
inﬂuenza among adults (15 to 64 years old). High numbers of
hospital and ICU admissions were reported among elderly [11],
Fig. 2. All-cause mortality pooled from 24 European countries based on the EuroMOMO algorithm, by age group, week 01/2014 to week 20/2018.
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supporting increased disease impact especially among adults and
elderly. In contrast, the inﬂuenza-attributable mortality among
children <15 years of age was at the same level or lower than
previous seasons.
During the 2017/18 season, inﬂuenza B/Yamagata circulated
widely and dominated over mixed inﬂuenza A subtypes. Many
European countries experienced a marked excess mortality among
the elderly similar to that observed during the A(H3N2) dominated
seasons 2014/15 and 2016/17. This observation challenges the
common perception that inﬂuenza B has only a modest impact on
severe illness and mortality in the elderly population [24,25].
Published data on burden of inﬂuenza B in Europe is scarce [26].
However, a global review found that inﬂuenza B can pose a sig-
niﬁcant burden [27]. A Canadian study reported that the age dis-
tribution differ between the two B lineages, with a substantially
higher median age for B/Yamagata [28]. This may explain the
pattern in mortality observed during the B/Yamagata dominated
2017/18 season. However, A(H3N2) circulated too, and may also
have contributed to the excess mortality among elderly. It is also
possible that the European population was more susceptible to B/
Yamagata infection as B/Victoria has been the main circulating
lineage since the 2014/15 season and before that 2012/13 [11].
Though B/Yamagata was included in the WHO recommended vac-
cines from 2012/13 to 2015/16, the immunity in the populationmay
be limited due to low coverage, as inﬂuenza vaccination pro-
grammes in most European countries target only risk groups in
order to minimise severe outcomes, and do not consider indirect
protection and herd immunity. However, even though inﬂuenza B/
Yamagata was not included in the 2017/18 season's trivalent
inﬂuenza vaccine, which was most widely used in European
countries, the vaccine effectiveness against inﬂuenza B has been
estimated to 36-54% [29], maybe due to preserved immunity from
previous immunisation (infection or vaccination) [30] or cross
protection.
Limitations
Pooled estimates can both mask and accentuate differences
between countries in excess and inﬂuenza-attributable mortality.
Therefore, an important component in the EuroMOMO procedures
is the initial national analyses to reveal excess mortality at country
level, while the pooled analyses may reveal small increases in
mortality not immediately recognisable locally. For example, an
excess mortality among adults aged 15-64 years was detected in
the pooled analyses in the current season, but only in few of the
countries' national analyses.
All analyses of inﬂuenza-attributable mortality were per-
formed at the EuroMOMO hub, using IA data from TESSy. This
has the advantage of using common, standardised IA data, but
also has limitations e.g. missing a local review and validation
process.
The Goldstein Index: ILI x PP, represents the most conservative
indicator of inﬂuenza activity and was the IA indicator used in the
FluMOMO model [7,14]. However, not all countries report ILI, and
we used ARI or Intensity, where ILI was unavailable. Further,
virology data from TESSy were not age-stratiﬁed; hence, the same
all-ages-PP was used in each of the age groups, which may have
masked differences between age groups. The impact of these lim-
itations in IA should be investigated.
Mortality attributable to inﬂuenza differentiated by type/sub-
type may provide an improved understanding of the burden
attributable to each type/sub-type. However, the nearly equal
pattern in the circulation of inﬂuenza A and B in the 2017/18 season
(Fig. 1) introduced collinearity between the inﬂuenza types i.e.
making the effects difﬁcult to separate. Further, splitting the IA
parameter into type/sub-type substantially reduced the statistical
power making the model unstable. Therefore, it was not feasible to
make type/sub-type differentiated estimates.
Heterogeneity in mortality patterns between countries may
reﬂect some real differences, possibly related to differences in
inﬂuenza circulation by type/sub-type, country-speciﬁc population
susceptibility, differences in inﬂuenza vaccine uptake, varying from
5 to 75% coverage among elderly [31], or vaccine effectiveness.
Therefore, regional analyses have the potential to provide added
value. However, with few participating countries in some regions of
Europe, this was not explored further.
We extended the estimated excess mortality in the participating
countries to the European population, this extension is uncertain
as potential differences in climate, inﬂuenza transmission, under-
lying immunity and access to health care between the participating
and non-participating European countries were not taken into
account.
Table 2
Cumulated pooled all-cause excess mortality during the winter season based on the EuroMOMO algorithm, by season (week 40 to week 20) 2012/13 to 2017/18
Season 2012/13 2013/14 2014/15 2015/16 2016/17 2017/18
Circulating types
of inﬂuenza1
A(H1N1)pdm09 (47%)
B/Yamagata (53%)
Mixed A (98%)
B/Yamagata (2%)
A(H3N2) (67%)
B/Yamagata (33%)
A(H1N1)pdm09 (56%)
B/Victoria (44%)
A(H3N2) (89%)
Mixed B (11%)
Mixed A (33%)
B/Yamagata (67%)
WHO recommended
vaccine strains
A(H3N2)
A(H1N1)pdm09
B/Yamagata
A(H3N2)
A(H1N1)pdm09
B/Yamagata
A(H3N2)
A(H1N1)pdm09
B/Yamagata
A(H3N2)
A(H1N1)pdm09
B/Yamagata
A(H3N2)
A(H1N1)pdm09
B/Victoria
A(H3N2)
A(H1N1)pdm09
B/Victoria
Age groups Excess all-cause mortality per 100,000 population (95% CI)
0-4 1.14 (0.36;1.92) 1.76 (1.00;2.52) 1.38 (0.62;2.14) 2.42 1.70;3.14) 0.88 (0.15;1.60) -1.07 (-1.72;-0.41)
5-14 0.49 (0.31;0.67) 0.18 (0.02;0.35) 0.51 (0.35;0.67) 0.50 (0.34;0.66) 0.18 (0.03;0.34) 0.13 (-0.01;0,27)
15-64 2.09 (1.66;2.53) 1.67 (1.22;2.12) 5.94 (5.53;6.35) 4,85 (4.47;5.23) 3.49 (3.13;3.86) 5.03 (4.71;5.35)
65 88.20 (81.42;94.99) -12.46 (-20.11;-4.79) 214.17 (207.60;220.74) 14.71 (8.82;20.60) 152.79 (146.43;159.16) 154.12 (149.35;158.89)
Total 17.25 (15.96;18.55) -1.39 (-2.96;0.18) 43.63 (42.30;44.96) 5.37 (4.15;6.58) 29.21 (27.97;30.45) 33.81 (32.76;34.85)
Number of countries
participating
14 17 18 19 21 24
Population covered
(millions)
268 275 279 340 345 361
Note: Excess mortality is deﬁned as observed mortality minus baseline.
1) For 2012/13 and 2013/14 all EU/EEA sentinel samples reported to ECDC (https://ecdc.europa.eu/en/seasonal-inﬂuenza/surveillance-and-disease-data/aer). From 2014/15
and onward, all European sentinel samples reported to WHO/ECDC (http://ﬂunewseurope.org/Archives).
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Fig. 3. Cumulated excess mortality pooled from 24 European countries based on the EuroMOMO algorithm, by age group and week, for the inﬂuenza seasons 2012/13 to 2017/18.
J. Nielsen et al. / Clinical Microbiology and Infection 25 (2019) 1266e12761272
Fig. 4. All-cause mortality pooled from 24 European countries based on the FluMOMO algorithm, by age group, week 01/2014 to week 20/2018. Participating countries: Austria,
Belgium, Berlin (Germany), Denmark, England (UK), Estonia, Finland, Franc, Greece, Hesse (Germany), Hungary, Ireland, Italy, Luxembourg, Malta, Netherlands, Northern Ireland
(UK), Norway, Portugal, Scotland (UK), Spain, Sweden, Switzerland, Wales (UK)
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Fig. 5. Cumulated inﬂuenza attributable mortality pooled from 24 European countries based on the FluMOMO algorithm, by age group and week, for the inﬂuenza seasons 2012/13
to 2017/18.
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Conclusion
Using the existing EuroMOMO and FluMOMO models and
available inﬂuenza and temperature data, we have shown that
during the 2017/18 season, dominated by inﬂuenza B/Yamagata,
Europe experienced a marked excess mortality among adults and
elderly attributable to inﬂuenza. The impact of the 2017/18 inﬂu-
enza epidemic on mortality was similar to that of the previous
inﬂuenza A(H3N2) dominated seasons in 2014/15 and 2016/17. The
European number of deaths attributable to inﬂuenzawas estimated
to be 152 thousand persons. We found a lower inﬂuenza-
attributable mortality compared to excess mortality, which may
indicated that other circulating pathogens might also have
contributed to the all-cause excess mortality.
A non-negligible circulation of A(H3N2) may have contributed
to the high excess mortality among elderly. However, the large
inﬂuenza-attributable mortality burden in elderly during an
inﬂuenza B dominated season challenge the common perception of
inﬂuenza B primarily affecting children and young adults and
having limited impact in the elderly population.
Finally, our ﬁndings suggest that the overall inﬂuenza-related
mortality is signiﬁcantly higher than inﬂuenza mortality based on
respiratory causes of deaths alone. However, as data on mortality
are crucial to informing policies pertaining prevention and control
of inﬂuenza, in particular seasonal inﬂuenza vaccination programs,
further studies are needed to fully assess the burden of all-cause
and cause-speciﬁc inﬂuenza mortality.
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